-
Company Insights
Boehringer Ingelheim – Digital Transformation Strategies
Boehringer Digital Transformation Strategies Report Overview Boehringer Ingelheim (Boehringer) is tapping into key disruptive technologies including AI, big data, digital therapeutics, and cloud, among others to enhance its operational efficiency and product offerings. The annual ICT spending of Boehringer is estimated at $1.0 billion for 2022. A major share of this spending is earmarked for acquiring software, ICT services and hardware from vendors. Boehringer is a family-owned pharmaceutical company engaged in the discovery, development, manufacture, and marketing of human pharmaceuticals...
-
Product Insights
Boehringer Ingelheim – BioNex Biopharmaceutical Plant – Lower Austria
Equip yourself with the essential tools needed to make informed and profitable decisions with our Boehringer Ingelheim - BioNex Biopharmaceutical Plant - Lower Austria report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Boehringer Ingelheim – Xochimilco Oral Antidiabetic Plant Expansion – Mexico City
Equip yourself with the essential tools needed to make informed and profitable decisions with our Boehringer Ingelheim - Xochimilco Oral Antidiabetic Plant Expansion - Mexico City report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Boehringer Ingelheim – Athens Animal Health Global Innovation Center – Georgia
Equip yourself with the essential tools needed to make informed and profitable decisions with our Boehringer Ingelheim - Athens Animal Health Global Innovation Center - Georgia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Boehringer Ingelheim – Jonage Vaccine Production Facility – Auvergne-Rhone-Alpes
Equip yourself with the essential tools needed to make informed and profitable decisions with our Boehringer Ingelheim - Jonage Vaccine Production Facility - Auvergne-Rhone-Alpes report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Company Profile
![]()
Boehringer Ingelheim International GmbH – Company Profile
Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for...
Add to Basket -
Sector Analysis
NewDiabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BI-765128 in Diabetic Retinopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BI-765128 in Diabetic Retinopathy Drug Details: BI-765128 is under development for the treatment of diabetic retinopathy...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YH-25724 in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.YH-25724 in Obesity Drug Details: YH-25724 is under development for the treatment of non-alcoholic steatohepatitis (NASH),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Survodutide in Type 2 Diabetes
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Survodutide in Type 2 Diabetes Drug Details: BI-456906 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Survodutide in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Survodutide in Obesity Drug Details: BI-456906 is under development for the treatment of non-alcoholic steatohepatitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BI-3702025 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BI-3702025 in Ovarian Cancer Drug Details: BI-3702025 (NBE-002) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YH-25724 in Non Alcoholic Fatty Liver Disease (NAFLD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.YH-25724 in Non Alcoholic Fatty Liver Disease (NAFLD) Drug Details: YH-25724 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YH-25724 in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. YH-25724 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: YH-25724 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NPY2r Agonist in Cardiometabolic Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NPY2r Agonist in Cardiometabolic Disease Drug Details: The therapeutic candidate is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Hemodynamic Modulator 1 in Cardiometabolic Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Hemodynamic Modulator 1 in Cardiometabolic DiseaseDrug Details:The drug candidate is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BT-8009 in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BT-8009 in Esophageal Cancer Drug Details: BT-8009 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IOV-1042 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IOV-1042 in Solid Tumor Drug Details: IOV-1042 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AT-193 in Hidradenitis Suppurativa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AT-193 in Hidradenitis Suppurativa Drug Details: AT-193 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Prosthetic Joint Infection (PJI) in Prosthetic Joint infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Prosthetic Joint Infection (PJI) in Prosthetic Joint infections Drug Details: Biologic is under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.